Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader, showing it effectively modulates multiple inflammatory pathways in inflammatory bowel disease (IBD) models. KT-579 demonstrated comparable or superior activity to existing therapies by reducing key inflammatory cytokines and improving disease markers. The drug is currently in a Phase 1 trial with healthy volunteers, focusing on safety and IRF5 degradation, with results expected in the second half of 2026. This novel oral treatment could offer a new option for patients with complex autoimmune diseases like IBD.
The global beadlets capsule market is projected to grow from $467.26 million in 2025 to $968.45 million by 2035, at a compound annual growth rate of 6.85%. Growth is driven by rising demand in pharmaceutical and nutraceutical sectors, fueled by advan...
U.S. spot Bitcoin ETFs experienced $526.64 million in net outflows last week, extending their losing streak to eight consecutive weeks, the longest since these ETFs began trading. Spot Ethereum ETFs also posted $13.67 million in outflows, reflecting ...
Bitcoin climbed to $63,700, its highest in two weeks, driven by a 2.7% weekend gain as traders prepare for a week packed with important U.S. economic data. The Federal Reserve's meeting minutes, the first under new Chairman Kevin Warsh, along with jo...
Molecular Partners is progressing its Phase 1/2a clinical trial of MP0712, a Radio-DARPin therapeutic targeting DLL3 for small cell lung and neuroendocrine cancers, with patient dosing ongoing at five US centers. Initial clinical data are expected wi...
Cal-Maine Foods is recognized for its dominant industry position, strong competitive advantages, and solid financial health. The company benefits from low costs, recent acquisitions, and growth in specialty eggs, which supports its earnings potential...
